이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Kancera 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Peter Selin

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.03%
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	12.5yrs

최근 관리 업데이트

Recent updates

CEO

Peter Selin (51 yo)

less than a year

테뉴어

Mr. Peter Selin serves as Chief Executive Officer of Kancera AB (publ) since July 1, 2023. He had been an Executive Vice president of Corporate Development & Finance at Kancera AB (publ) since May 01, 2022...

리더십 팀

이름	위치	테뉴어	보상	소유권
Thomas Olin	Executive VP	less than a year	SEK 3.57m	0.30% SEK 650.0k
Peter Selin	Chief Executive Officer	less than a year	데이터 없음	0.026% SEK 56.1k
Hans Richter	Chief Financial Officer	no data	데이터 없음	데이터 없음
Niclas Brynne	Head of Clinical Development	no data	데이터 없음	0.024% SEK 51.9k
Markus Jerling	Chief Medical Officer	less than a year	데이터 없음	데이터 없음

1.0yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 관리: KAN 의 관리팀은 경험 (평균 재직 기간 0.9 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Thomas Olin	Executive VP	14.5yrs	SEK 3.57m	0.30% SEK 650.0k
Charlotte Edenius	Independent Director	8.1yrs	SEK 125.00k	0% SEK 0
Håkan Mellstedt	Independent Director	14.5yrs	SEK 125.00k	0.17% SEK 383.6k
Erik Nerpin	Independent Chairman of the Board	14.5yrs	SEK 175.00k	0.24% SEK 522.7k
Carl-Henrik Heldin	Independent Director	12.5yrs	SEK 125.00k	0.066% SEK 144.8k
Anders Gabrielsen	Independent Director	5.9yrs	SEK 125.00k	데이터 없음
Petter Brodin	Independent Director	3.2yrs	SEK 75.00k	데이터 없음

12.5yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: KAN 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 12.4 년).

Kancera 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Kancera AB (publ) Announces Executive Changes

Kancera AB (publ), Annual General Meeting, May 27, 2024

Kancera AB (publ) Appoints Markus Jerling as Chief Medical Officer

Kancera AB (publ) Appoints Peter Selin as New Chief Executive Officer, Effective from July 1 2023

Independent Director recently sold kr58k worth of stock

Insufficient new directors

Recent updates

Kancera AB's Fractal Study Results to Be Presented at the ESC 2024 Conference

New major risk - Financial position

Kancera AB (publ) Announces Executive Changes

Kancera AB (publ) Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects

New major risk - Shareholder dilution

Forecast breakeven date pushed back to 2025

Kancera AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 73.011989 million.

New major risk - Financial position

New major risk - Share price stability

Kancera AB (publ) Reports Positive Top Line Results from the FRACTAL Study

We Think Kancera (STO:KAN) Needs To Drive Business Growth Carefully

Forecast breakeven date moved forward to 2024

Kancera AB (publ), Annual General Meeting, May 27, 2024

Kancera AB (publ) Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145

Kancera AB (publ) Appoints Markus Jerling as Chief Medical Officer

Kancera AB (publ) to Report Q3, 2023 Results on Nov 17, 2023

New major risk - Share price stability

Kancera AB (Publ) Announces Newly Published Research Publication Confirms the Potential for Kancera's Fractalkine Blocker KAND567 in Cardiovascular Disease

Is Kancera (STO:KAN) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

Kancera AB (publ) Reports Dosing of First Patient in the KANDOVA Study

Kancera AB (publ) Appoints Peter Selin as New Chief Executive Officer, Effective from July 1 2023

Independent Director recently sold kr58k worth of stock

Companies Like Kancera (STO:KAN) Are In A Position To Invest In Growth

Forecast to breakeven in 2025

Kancera AB (publ) Submits Regulatory Application to the Swedish Medical Products Agency to Conduct Clinical Studies of KAND567 in Ovarian Cancer

Insufficient new directors

Kancera AB (publ) Reports New Preclinical Results Supporting Potential for Its Ror1 Inhibitor in B-Cell Malignancies

Kancera AB (publ) Reports Promising Preclinical Results from Studies of Its Fractalkine Axis Blocking Drug Candidates in B-Cell Lymphoma

Kancera AB (publ) Reports Good Progress of Recruitment in Ongoing Phase IIa Study of Kand567 in Myocardial Infarction and the Decision to Allow for Recruitment of Additional Patients

Kancera AB (publ) Reports Convincing Preclinical Results and Decision to Initiate Clinical Development of KAND567 in Ovarian Cancer

We Think Kancera (STO:KAN) Can Afford To Drive Business Growth

Insufficient new directors

We're Hopeful That Kancera (STO:KAN) Will Use Its Cash Wisely

Insufficient new directors

Here's Why We're Watching Kancera's (STO:KAN) Cash Burn Situation

First quarter 2021 earnings released: kr0.029 loss per share (vs kr0.56 loss in 1Q 2020)

Insider recently bought kr65k worth of stock

We're Not Very Worried About Kancera's (STO:KAN) Cash Burn Rate

Full year 2020 earnings released: kr0.13 loss per share (vs kr0.18 loss in FY 2019)

New 90-day low: kr1.62

Here's Why We're Not Too Worried About Kancera's (STO:KAN) Cash Burn Situation

New 90-day low: kr2.23

New 90-day low: kr2.37

Kancera AB (publ) to Report Q3, 2021 Results on Nov 19, 2021

New 90-day high: kr3.98

First half earnings released

New 90-day high - kr2.96

Oncopeptides AB (publ) (OM:ONCO) agreed to acquire Kancera's drug development facility in Solna, Sweden.

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령